MAFLD高危人群的筛查和分层管理*

doi:10.3969/j.issn.1672-5069.2023.04.003

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (4): 463-465.doi: 10.3969/j.issn.1672-5069.2023.04.003

MAFLD高危人群的筛查和分层管理^*

张淮, 郑明华

325000 浙江省温州市温州医科大学附属第一医院病案信息统计室/医疗质量管理处(张淮);感染内科/浙江省慢性肝病重症化精准诊治与转化重点实验室(郑明华)

收稿日期:2023-04-11 出版日期:2023-07-10 发布日期:2023-07-21
通讯作者: 郑明华,E-mail:zhengmh@wmu.edu.cn
作者简介:张淮,男,29岁,医学硕士,中级统计师。主要从事疾病监测与统计学研究。E-mail: zhanghuai@wmu.edu.cn
基金资助:
^*国家自然科学基金资助项目(编号:82070588)

Screening and management of patients with metabolic dysfunction-associated fatty liver disease in high-risk populations

Zhang Huai, Zheng Minghua

Department of Biostatistics and Records Room, Medical Quality Management Office, First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China

Received:2023-04-11 Online:2023-07-10 Published:2023-07-21

摘要/Abstract

关键词: 代谢相关性脂肪性肝病, 筛查, 分层管理

Key words: Metabolic dysfunction-associated fatty liver disease, Screening, Risk stratification, Management

张淮, 郑明华. MAFLD高危人群的筛查和分层管理^*[J]. 实用肝脏病杂志, 2023, 26(4): 463-465.

Zhang Huai, Zheng Minghua. Screening and management of patients with metabolic dysfunction-associated fatty liver disease in high-risk populations[J]. Journal of Practical Hepatology, 2023, 26(4): 463-465.

参考文献

[1] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol,2020,73 (1): 202-209.
[2] Zhang H, Rios RS, Boursier J, et al. Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study. Chin Med J (Engl),2023,136(3):341-350.
[3] European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol,2016, 64 (6): 1388-1402.
[4] Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: A systematic review and Meta-analysis. Gastroenterology, 2020, 158 (6): 1611-1625.
[5] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol, 2019, 70 (1): 151-171.
[6] Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 2004,40 (6): 1387-1395.
[7] Kanwal F, Kramer JR, Duan Z, et al. Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans. Clin Gastroenterol Hepatol, 2016,14 (2): 301-308,e301-302.
[8] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64 (1): 73-84.
[9] Beste LA, Leipertz SL, Green PK, et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology, 2015, 149 (6): 1471-1482,e1475,quiz e1417-1478.
[10] Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380 (9859): 2095-2128.
[11] Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med, 2014,(12): 145.
[12] Mokdad AH, Forouzanfar MH, Daoud F, et al. Global burden of diseases, injuries, and risk factors for young people's health during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2016, 387 (10036): 2383-2401.
[13] Kanwal F, Kramer JR, Li L, Dai J, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology, 2020, 71 (3): 808-819.
[14] NCD Risk Factor Collaboration. Rigorous and timely data on major risk factors for non-communicable diseases for all of the world's countries. 2023-2-29. (Accessed at https://www.ncdrisc.org/index.html).
[15] Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology,2021,161 (5): 1657-1669.
[16] Lomonaco R, Godinez Leiva E, Bril F, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: The need for systematic screening. Diabetes Care, 2021, 44 (2): 399-406.
[17] Noureddin M, Jones C, Alkhouri N, et al. Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: A comprehensive cost-utility analysis. Gastroenterology, 2020, 159 (5): 1985-1987,e1984.
[18] Wright AP, Desai AP, Bajpai S, et al. Gaps in recognition and evaluation of incidentally identified hepatic steatosis. Dig Dis Sci, 2015, 60 (2): 333-338.
[19] Natarajan Y, Kramer JR, Yu X, et al. Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes. Hepatology, 2020, 72 (4): 1242-1252.
[20] Wu XX, Zheng KI, Boursier J, et al. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. E Clin Med,2021,41:101145.
[21] Tang LJ, Li G, Eslam M, et al. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. Hepatol Int, 2023, 17 (1): 190-201.
[22] Siddiqui MS, Yamada G, Vuppalanchi R, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol, 2019, 17 (9): 1877-1885,e1875.
[23] Feng G, Zhang X, Zhang L, et al. Novel urinary protein panels for the non-invasive diagnosis of non-alcoholic fatty liver disease and fibrosis stages. Liver Int, 2023,43(6):1234-1246.
[24] Canivet CM, Zheng MH, Qadri S, et al. Validation of the blood test MACK-3 for the noninvasive diagnosis of fibrotic NASH: an international study with 1924 patients. Clin Gastroenterol Hepatol, 2023[ahead of print].
[25] Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut, 2021, 70 (7): 1375-1382.
[26] Chuah KH, Wan Yusoff WNI, Sthaneshwar P, et al. MACK-3 (combination of HOMA, AST and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis. Liver Int, 2019, 39 (7): 1315-1324.
[27] Greenhill C. Diagnosis: new noninvasive test to diagnose NASH by analysing exhaled breath. Nat Rev Gastroenterol Hepatol, 2013, 10 (1): 4.
[28] Sinha R, Lockman KA, Homer NZM, et al. Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease. JHEP Rep, 2020, 2 (5): 100137.
[29] Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019, 156 (6): 1717-1730.
[30] Zhou YJ, Gao F, Liu WY, et al. Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther, 2021, 54 (4): 470-480.
[31] Cassinotto C, Lapuyade B, Guiu B, et al. Agreement between 2-dimensional shear wave and transient elastography values for diagnosis of advanced chronic liver disease. Clin Gastroenterol Hepatol, 2020, 18 (13): 2971-2979,e2973.
[32] Lefebvre T, Wartelle-Bladou C, Wong P, et al. Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis. Eur Radiol, 2019, 29 (12): 6477-6488.
[33] Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology, 2010, 51 (1): 121-129.
[34] Baldwin D, Chennakesavalu M, Gangemi A. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria. Surg Obes Relat Dis, 2019, 15 (12): 2123-2130.
[35] Panunzi S, Maltese S, Verrastro O, et al. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. Diabetes Obes Metab, 2021, 23 (4): 980-990.

MAFLD高危人群的筛查和分层管理^*

Screening and management of patients with metabolic dysfunction-associated fatty liver disease in high-risk populations

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

本文评价

[1]	符鑫, 刘悦, 彭鑫, 黄婷婷, 廖雪霞, 颜悦蓉. 采用高敏检测技术检测血清HBV DNA载量筛选低病毒血症的无偿献血人群隐匿性乙型肝炎病毒感染研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 169-172.
[2]	米朦, 卢秉久, 王学良, 王晓彤, 郑佳连. 代谢相关性脂肪性肝病患者血脂分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 653-656.
[3]	杨蕊旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查^*[J]. 实用肝脏病杂志, 2022, 25(2): 153-156.
[4]	曲颖, 蔡晓波, 张启迪, 陆伦根. 体检人群血清M2型抗线粒体抗体流行率调查^*[J]. 实用肝脏病杂志, 2022, 25(2): 203-206.
[5]	中国肝炎防治基金会肝细胞癌筛查和监测项目专家组. 慢性乙型肝炎病毒感染者肝细胞癌筛查和监测[J]. 实用肝脏病杂志, 2021, 24(6): 776-785.
[6]	朱南南, 蒋晓红, 周佳雁, 黄小琳, 刘雅旻. 2型糖尿病合并代谢相关性脂肪性肝病患者血尿酸水平变化和其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(6): 839-842.
[7]	首第文, 周永健, 徐豪明, 唐文娟, 骆庆玲, 梅情, 宁钢, 赵冲, 黄红丽, 曹创裕, 陈慧婷. 代谢相关性脂肪性肝病小鼠不同高脂饮食时期血糖水平和肠道菌群变化动态分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 661-664.
[8]	徐春玲, 苗重昌, 刘雨成, 张雪, 史曙光, 李树芸. 应用MRI多回波水脂分离技术评估代谢相关性脂肪性肝病患者肝脏脂肪含量的临床意义[J]. 实用肝脏病杂志, 2021, 24(2): 220-223.
[9]	杨晓玲, 张素梅. SGA、MNA和NRS2002评估失代偿期肝硬化患者营养状态应用价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 70-73.
[10]	中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 实用肝脏病杂志, 2019, 22(5): 624-635.
[11]	王琦, 谢雯. 孕妇乙型肝炎病毒感染筛查与管理^*[J]. 实用肝脏病杂志, 2019, 22(1): 9-12.
[12]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.
[13]	董雪莲, 张文均. 肝脏受控衰减参数检测早期无创发现代谢综合征人群价值分析^*[J]. 实用肝脏病杂志, 2018, 21(6): 868-871.